- The FDA designates Momenta Pharmaceuticals' (NASDAQ:MNTA +2.1%) oncology drug candidate necuparanib an Orphan Drug for the treatment of pancreatic cancer. Necuparanib is a heparan sulfate mimetic, derived from unfractionated heparin. It retains its antitumor properties while minimizing its anticoagulant activity.
- The company expects to complete part A of its Phase 1/2 study of necuparanib in combination with Abraxane and gemcitabine in the next several months. Phase 2 will commence in 2H 2014.
Momenta oncology drug gets orphan status
Recommended For You
More Trending News
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
MNTA | - | - |
Momenta Pharmaceuticals, Inc. |